Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Long-Term Investments (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Long-Term Investments data on record, last reported at $6.9 million in Q3 2025.

  • For Q3 2025, Long-Term Investments rose 21.96% year-over-year to $6.9 million; the TTM value through Sep 2025 reached $6.9 million, up 21.96%, while the annual FY2024 figure was $5.7 million, N/A changed from the prior year.
  • Long-Term Investments reached $6.9 million in Q3 2025 per COEP's latest filing, roughly flat from $6.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $75.8 million in Q1 2022 and bottomed at $5.7 million in Q3 2024.
  • Average Long-Term Investments over 4 years is $39.8 million, with a median of $33.1 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: plummeted 56.45% in 2022, then grew 21.96% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $75.8 million in 2021, then plummeted by 56.09% to $33.3 million in 2022, then tumbled by 82.89% to $5.7 million in 2024, then rose by 21.96% to $6.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $6.9 million in Q3 2025, $6.9 million in Q2 2025, and $6.9 million in Q1 2025.